Expert Interview
Discussing the Phase 2 Open-label Extension Study of Sanofi's novel anti-CD40L antibody, frexalimab, in patients with Multiple Sclerosis
Ticker(s): SNYInstitution: Johns Hopkins University
- Assistant Professor of Neurology at Johns Hopkins University
- Manages about 300 patients with Multiple Sclerosis and most frequently prescribes Ocrevus, dimethyl fumarate
- Research is aimed at understanding the pathogenesis of multiple sclerosis, particularly the processes that drive progressive disability such a neurodegeneration and remyelination failure
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
